XML 89 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborations (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Janssen Biotech Inc. |
Collaborative and license agreements |
Schedule of profit and cost sharing relationship | The following table shows the profit and cost sharing relationship between Janssen and AbbVie:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
United States - Janssen's share of profits (included in cost of products sold) |  | $ | 235 |  |  | $ | 282 |  |  | $ | 735 |  |  | $ | 849 |
International - AbbVie's share of profits (included in net revenues) |  | 199 |  |  | 210 |  |  | 619 |  |  | 676 |
Global - AbbVie's share of other costs (included in respective line items) |  | 24 |  |  | 38 |  |  | 74 |  |  | 120 |
Genentech, Inc. |
Collaborative and license agreements |
Schedule of profit and cost sharing relationship | The following table shows the profit and cost sharing relationship between Genentech and AbbVie:
|  | Three months ended September 30, |  | Nine months ended September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Genentech's share of profits, including royalties (included in cost of products sold) |  | $ | 286 |  |  | $ | 263 |  |  | $ | 790 |  |  | $ | 733 |
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) |  | 13 |  |  | 10 |  |  | 26 |  |  | 25 |
AbbVie's share of development costs (included in R&D) |  | 15 |  |  | 21 |  |  | 47 |  |  | 63 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_GenentechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |